No Data
No Data
Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results
Edgewise Therapeutics' New $175M Stock Sale Agreement and Previous Termination
Express News | Edgewise Therapeutics - Sales Agreement Prospectus Covering Offering of up to $175 Mln of Common Stock That May Be Issued Under Sales Agreement
Express News | Edgewise Therapeutics Files for Mixed Shelf Offering, Size Not Disclosed - Filing
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15,
Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating
Edgewise Therapeutics (EWTX) has an average rating of buy and price targets ranging from $24 to $48, according to analysts polled by Capital IQ. Price: 19.52, Change: -0.48, Percent Change: -2.40